Biotech '24: GLP1 (view performance)

High-performing operators in the GLP-1 theme are expected to exhibit selective but strategic hiring, prioritizing roles crucial for advancing their innovative pipelines and navigating a complex market. We should anticipate strong demand for talent in clinical operations, regulatory affairs, and manufacturing, especially as oral GLP-1 formulations and next-generation multi-agonists progress through late-stage trials and towards commercialization. Specialized R&D roles focusing on novel mechanisms like muscle preservation, biased agonism for improved tolerability, and combination therapies will also be critical. Furthermore, with the evolving landscape of insurance coverage and the rise of direct-to-consumer models, companies will likely invest in market access, commercialization, and patient support teams. An increase in hiring for data scientists and AI engineers to support drug discovery, clinical trial design, and real-world evidence generation would also confirm strong theme execution. Conversely, a warning of deterioration would be indicated by hiring freezes or reductions in core GLP-1 development functions, a lack of investment in R&D for next-generation therapies, or a failure to build out robust commercial and market access teams despite new product approvals.

The GLP-1 market is undergoing a significant transformation, moving beyond first-generation injectables to embrace novel formulations and mechanisms. A major emerging trend is the rapid ascent of **oral GLP-1 medications**, with Novo Nordisk's oral Wegovy launching in January 2026 and Eli Lilly's Foundayo (orforglipron) in April 2026. These oral options are expected to dramatically expand market access by appealing to patients hesitant about injections. Another critical trend is the development of **multi-agonist and combination therapies**, targeting not just GLP-1 but also GIP (e.g., tirzepatide/Zepbound) and glucagon (e.g., retatrutide, survodutide), which are demonstrating superior weight loss efficacy. Combination therapies with amylin analogs (e.g., CagriSema, petrelintide) are also gaining traction, with a focus on **muscle preservation** and improved tolerability, addressing a key limitation of current GLP-1s. The scope of GLP-1 therapies is broadening significantly, with **expanded indications** beyond diabetes and obesity to include cardiovascular outcomes, heart failure with preserved ejection fraction (HFpEF), peripheral artery disease, kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH). This expansion positions GLP-1s as versatile therapies for multiple organ systems. The **affordability and access landscape remains complex**, with commercial insurance coverage for weight loss GLP-1s becoming more restrictive, leading to a rise in direct-to-consumer (DTC) models and cash-pay options. Efforts to expand Medicare and Medicaid coverage are ongoing but face significant cost hurdles. Finally, there's an increasing emphasis on the **quality of weight loss**, focusing on maximizing fat loss while preserving lean muscle mass and improving tolerability through mechanisms like biased agonism to reduce gastrointestinal side effects.